Advertisement

Document › Details
BioNTech AG. (12/21/17). "Press Release: BioNTech to Present at 36th Annual J.P. Morgan Healthcare Conference". Mainz.
![]() |
Region | San Francisco, CA |
Country | United States (USA) | |
![]() |
Organisation | BioNTech AG |
Today | BioNTech SE (Nasdaq: BNTX) | |
Group | BioNTech (Group) | |
Organisation 2 | ICR Inc. | |
Group | ICR (Group) | |
![]() |
Product | J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco |
Product 2 | mRNA-based vaccine | |
![]() |
Index term | BioNTech–JPMorgan Chase: investor conference, 201801 supply service BioNTech presents at JP Morgan Healthcare Conference 2018 |
Index term 2 | BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US | |
![]() |
Person | Marett, Sean (BioNTech 202012 CBO + CCO 201506 COO before Evotec) |
Person 2 | Buth, Ines-Regina (akampion 200901 before Micromet Head Investor Relations before Lion Bioscience) | |
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference that is being held in San Francisco, CA from January 8-11, 2018. The Company’s presentation is scheduled for Tuesday, January 9 at 9:00 AM Pacific Standard Time.
Mr. Marett will provide an overview of the Company´s strategy as well as an update on its development programs, including its expanding clinical pipeline, in-house manufacturing capabilities, and a summary of human clinical data recently published in Nature publication on its neo-epitope based individualized mRNA cancer immunotherapeutic.
For more information, please contact:
General Inquiries:
BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273
Email: Regina.Jehle@biontech.de
US Media & Investor Inquiries:
ICR Healthcare
James Heins / Stephanie Carrington
Tel: +1 203 682 8251
Tel: +1 646 277 1282
Email: James.Heins@icrinc.com
Email: Stephanie.Carrington@icrinc.com
International Media & Investor Inquiries:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768
Email: info@akampion.com
About BioNTech AG
BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, a member of the Roche Group, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.
More information about BioNTech is available at www.biontech.de.
Record changed: 2020-12-27 |
Advertisement

More documents for BioNTech (Group)
- [1] BioNTech SE. (12/29/20). "Press Release: Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of Comirnaty". New York, NY & Mainz....
- [2] BioNTech SE. (12/23/20). "Press Release: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine". New York, NY & Mainz....
- [3] BioNTech SE. (12/21/20). "Press Release: Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine". New York, NY & Mainz....
- [4] BioNTech SE. (12/21/20). "Press Release: Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine". New York, NY & Mainz....
- [5] BioNTech SE. (12/19/20). "Press Release: Pfizer and BioNTech Receive Conditional Marketing Authorization by Swissmedic for COVID-19 Vaccine". Zürich & Mainz....
- [6] BioNTech SE. (12/16/20). "Press Release: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine". Mainz & Shanghai....
- [7] BioNTech SE. (12/12/20). "Press Release: U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older". New York, NY & Mainz....
- [8] BioNTech SE. (12/11/20). "Press Release: Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19". New York, NY & Mainz....
- [9] BioNTech SE. (11/25/20). "Press Release: BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies". Mainz & London....
- [10] BioNTech SE. (11/11/20). "Press Release: Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19". New York, NY & Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
» top